We are analyzing https://link.springer.com/article/10.1245/s10434-014-4046-2.

Title:
Preoperative FDG-PET Predicts Early Recurrence and a Poor Prognosis After Resection of Pancreatic Adenocarcinoma | Annals of Surgical Oncology
Description:
The aim of this study was to evaluate the clinical utility of preoperative 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic predictor of resectable pancreatic adenocarcinoma. A total of 128 patients with resected pancreatic adenocarcinoma who preoperatively underwent FDG-PET examinations were studied. The maximum standard uptake value (SUVmax) was calculated for each primary lesion. A receiver operating characteristics (ROC) curve was constructed to estimate the optimal cutoff value of the SUVmax. In order to determine which outcomes of interest were appropriately demonstrated, ROC curve analyses were conducted for six outcomes: 6-, 12-, and 24-month disease-free survival (DFS), and 6-, 12-, and 24-month overall survival (OS). A multivariate analysis was conducted to identify prognostic factors. The ROC curves revealed that the SUVmax predicted the 6-month DFS most optimally (area under the curve 0.757), with a cutoff value of 6.0. Of the 69 patients with an SUVmax ≥ 6.0, 34 (49 %) developed recurrence within 6 months. In contrast, only 3 of 59 (5 %) patients with an SUVmax < 6.0 exhibited early recurrence (p < 0.001). The median OS time was 37 months in patients with an SUVmax < 6.0 and 18 months in patients with an SUVmax ≥ 6.0 (p < 0.001). The multivariate analysis revealed lymph node metastasis (hazard ratio [HR] 2.31; p = 0.001) and an SUVmax ≥ 6.0 (HR 2.05; p = 0.002) to be significantly correlated with a poor survival. An SUVmax ≥ 6.0 was a significant predictor of early postoperative recurrence and subsequent poor survival following resection of pancreatic adenocarcinoma.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don't see any clear sign of profit-making.

Many websites are intended to earn money, but some serve to share ideas or build connections. Websites exist for all kinds of purposes. This might be one of them. Link.springer.com could be getting rich in stealth mode, or the way it's monetizing isn't detectable.

Keywords {🔍}

article, google, scholar, pubmed, pancreatic, cancer, surg, prognostic, emission, tomography, patients, adenocarcinoma, positron, survival, oncol, preoperative, resection, ann, cas, recurrence, resectable, suvmax, lymph, carcinoma, node, pancreas, early, prognosis, sugiura, uptake, privacy, cookies, content, analysis, fdgpet, uesaka, month, ratio, fluorodeoxyglucose, publish, search, predicts, poor, yamamoto, teiichi, mizuno, ffluorodeoxyglucose, predictor, results, access,

Topics {✒️}

2-deoxy-2-fluoro[18f]-d-glucose 24-month disease-free survival positron emission tomography month download article/chapter 18f-fdg pet/ct small-cell lung cancer performing fdg-pet/ct katsuhiko uesaka declare hepato-biliary-pancreatic surgery early postoperative recurrence yukiyasu okamura md takeshi aramaki md receiver operating characteristics masahiro endo surgical oncology aims resectable pancreatic cancer full article pdf resected pancreatic adenocarcinoma privacy choices/manage cookies pancreatic head cancer resectable pancreatic adenocarcinoma related subjects pancreatic adenocarcinoma treated invasive ductal carcinoma teiichi sugiura md recurrent pancreatic cancer prognostic predictive early recurrence takashi mizuno md population-based analysis article yamamoto lymph node metastases lymph node ratio preoperative serum ca19-9 roc curves revealed metastatic lymph nodes pancreatic cancer resection biliary tract carcinoma adjuvant concurrent chemoradiotherapy long-term survival intrapancreatic nerve invasion acr practice guideline article annals shizuoka cancer center independent prognostic factor important prognostic factor strongest prognostic factor conditions privacy policy progression-free maximum standard uptake

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Preoperative FDG-PET Predicts Early Recurrence and a Poor Prognosis After Resection of Pancreatic Adenocarcinoma
         description: The aim of this study was to evaluate the clinical utility of preoperative 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic predictor of resectable pancreatic adenocarcinoma. A total of 128 patients with resected pancreatic adenocarcinoma who preoperatively underwent FDG-PET examinations were studied. The maximum standard uptake value (SUVmax) was calculated for each primary lesion. A receiver operating characteristics (ROC) curve was constructed to estimate the optimal cutoff value of the SUVmax. In order to determine which outcomes of interest were appropriately demonstrated, ROC curve analyses were conducted for six outcomes: 6-, 12-, and 24-month disease-free survival (DFS), and 6-, 12-, and 24-month overall survival (OS). A multivariate analysis was conducted to identify prognostic factors. The ROC curves revealed that the SUVmax predicted the 6-month DFS most optimally (area under the curve 0.757), with a cutoff value of 6.0. Of the 69 patients with an SUVmax ≥ 6.0, 34 (49 %) developed recurrence within 6 months. In contrast, only 3 of 59 (5 %) patients with an SUVmax < 6.0 exhibited early recurrence (p < 0.001). The median OS time was 37 months in patients with an SUVmax < 6.0 and 18 months in patients with an SUVmax ≥ 6.0 (p < 0.001). The multivariate analysis revealed lymph node metastasis (hazard ratio [HR] 2.31; p = 0.001) and an SUVmax ≥ 6.0 (HR 2.05; p = 0.002) to be significantly correlated with a poor survival. An SUVmax ≥ 6.0 was a significant predictor of early postoperative recurrence and subsequent poor survival following resection of pancreatic adenocarcinoma.
         datePublished:2014-09-05T00:00:00Z
         dateModified:2014-09-05T00:00:00Z
         pageStart:677
         pageEnd:684
         sameAs:https://doi.org/10.1245/s10434-014-4046-2
         keywords:
            Overall Survival
            Pancreatic Cancer
            Standardize Uptake Value
            Receiver Operating Characteristic
            Resectable Pancreatic Cancer
            Surgical Oncology
            Oncology
            Surgery
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1245%2Fs10434-014-4046-2/MediaObjects/10434_2014_4046_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1245%2Fs10434-014-4046-2/MediaObjects/10434_2014_4046_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1245%2Fs10434-014-4046-2/MediaObjects/10434_2014_4046_Fig3_HTML.gif
         isPartOf:
            name:Annals of Surgical Oncology
            issn:
               1534-4681
               1068-9265
            volumeNumber:22
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer US
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Tatsuma Yamamoto
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Teiichi Sugiura
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Takashi Mizuno
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yukiyasu Okamura
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Takeshi Aramaki
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Masahiro Endo
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Katsuhiko Uesaka
               affiliation:
                     name:Shizuoka Cancer Center
                     address:
                        name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Preoperative FDG-PET Predicts Early Recurrence and a Poor Prognosis After Resection of Pancreatic Adenocarcinoma
      description: The aim of this study was to evaluate the clinical utility of preoperative 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) as a prognostic predictor of resectable pancreatic adenocarcinoma. A total of 128 patients with resected pancreatic adenocarcinoma who preoperatively underwent FDG-PET examinations were studied. The maximum standard uptake value (SUVmax) was calculated for each primary lesion. A receiver operating characteristics (ROC) curve was constructed to estimate the optimal cutoff value of the SUVmax. In order to determine which outcomes of interest were appropriately demonstrated, ROC curve analyses were conducted for six outcomes: 6-, 12-, and 24-month disease-free survival (DFS), and 6-, 12-, and 24-month overall survival (OS). A multivariate analysis was conducted to identify prognostic factors. The ROC curves revealed that the SUVmax predicted the 6-month DFS most optimally (area under the curve 0.757), with a cutoff value of 6.0. Of the 69 patients with an SUVmax ≥ 6.0, 34 (49 %) developed recurrence within 6 months. In contrast, only 3 of 59 (5 %) patients with an SUVmax < 6.0 exhibited early recurrence (p < 0.001). The median OS time was 37 months in patients with an SUVmax < 6.0 and 18 months in patients with an SUVmax ≥ 6.0 (p < 0.001). The multivariate analysis revealed lymph node metastasis (hazard ratio [HR] 2.31; p = 0.001) and an SUVmax ≥ 6.0 (HR 2.05; p = 0.002) to be significantly correlated with a poor survival. An SUVmax ≥ 6.0 was a significant predictor of early postoperative recurrence and subsequent poor survival following resection of pancreatic adenocarcinoma.
      datePublished:2014-09-05T00:00:00Z
      dateModified:2014-09-05T00:00:00Z
      pageStart:677
      pageEnd:684
      sameAs:https://doi.org/10.1245/s10434-014-4046-2
      keywords:
         Overall Survival
         Pancreatic Cancer
         Standardize Uptake Value
         Receiver Operating Characteristic
         Resectable Pancreatic Cancer
         Surgical Oncology
         Oncology
         Surgery
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1245%2Fs10434-014-4046-2/MediaObjects/10434_2014_4046_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1245%2Fs10434-014-4046-2/MediaObjects/10434_2014_4046_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1245%2Fs10434-014-4046-2/MediaObjects/10434_2014_4046_Fig3_HTML.gif
      isPartOf:
         name:Annals of Surgical Oncology
         issn:
            1534-4681
            1068-9265
         volumeNumber:22
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer US
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Tatsuma Yamamoto
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Teiichi Sugiura
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Takashi Mizuno
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yukiyasu Okamura
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Takeshi Aramaki
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Masahiro Endo
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Katsuhiko Uesaka
            affiliation:
                  name:Shizuoka Cancer Center
                  address:
                     name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Annals of Surgical Oncology
      issn:
         1534-4681
         1068-9265
      volumeNumber:22
Organization:
      name:Springer US
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Shizuoka Cancer Center
      address:
         name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
         type:PostalAddress
      name:Shizuoka Cancer Center
      address:
         name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Tatsuma Yamamoto
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
               type:PostalAddress
            type:Organization
      name:Teiichi Sugiura
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Takashi Mizuno
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
               type:PostalAddress
            type:Organization
      name:Yukiyasu Okamura
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
               type:PostalAddress
            type:Organization
      name:Takeshi Aramaki
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
               type:PostalAddress
            type:Organization
      name:Masahiro Endo
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
               type:PostalAddress
            type:Organization
      name:Katsuhiko Uesaka
      affiliation:
            name:Shizuoka Cancer Center
            address:
               name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
      name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
      name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
      name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
      name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
      name:Division of Diagnostic Radiology, Shizuoka Cancer Center, Shizuoka, Japan
      name:Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(133)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.2s.

LINK . SPRINGER . COM {}